Plus   Neg

Tenax Therapeutics' Phase II Pulmonary Hypertension Trial Produces Mixed Results

Tenax Therapeutics Inc.'s (TENX) phase II trial, which evaluated Levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction, has produced mixed results.

In the study, dubbed HELP, the primary endpoint of the change from baseline Pulmonary capillary wedge pressure (PCWP) with bicycle exercise (25Watts) at week 6 following five weekly infusions of Levosimendan post-randomization did not demonstrate a statistically significant reduction from baseline.

However, Levosimendan did demonstrate a statistically significant reduction in PCWP compared to baseline and placebo when the measurements at rest, with legs up and on exercise, were combined, the Company noted.

The trial also demonstrated a statistically significant improvement in 6-minute walk distance of 29 meters, which was the secondary endpoint - a validated and accepted endpoint in many pulmonary hypertension registration trials.

TENX closed Monday's trading at $1.45, up 0.69%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Brazos Electric Power Cooperative Inc., the largest power generation and transmission cooperative in Texas, filed for Chapter 11 bankruptcy protection citing a huge bill from the state's grid operator following major outages recently amid the winter storm. Brazos received a $1.8 billion bill from electricity grid operator Electric Reliability Council of Texas or ERCOT. El Abuelito Cheese is recalling certain types of cheese and cheese products for fear of potential contamination with Listeria Monocytogenes, a deadly bacteria, the U.S. Food & Drug Administration said in a statement. The recall involves Queso Fresco (Fresh, soft cheese), Quesillo (Oaxaca, string cheese), and Requeson (Ricotta) products. Technology company CAE Inc. (CAE.TO, CAE) agreed Monday to acquire the military training division of aerospace and defense technology firm L3Harris Technologies Inc. (LHX) for $1.05 billion, subject to customary adjustments. The acquisition will expand CAE's position as a platform-agnostic training...
Follow RTT